10-Q: CVS Health Reports Q2 Earnings Decline Amidst Major Litigation Charges and Strategic Divestitures

CVS Health Corporation reported a significant drop in second-quarter net income and diluted EPS, primarily driven by over $800 million in litigation charges and losses from exiting certain Accountable Care programs, despite overall revenue growth.

Summary

• Total revenues increased by 8.4% to $98,915 million for the three months ended June 30, 2025, compared to $91,234 million in the prior year.
• Net income attributable to CVS Health decreased by 42.3% to $1,021 million for the three months ended June 30, 2025, down from $1,770 million in the same period last year.
• Diluted earnings per share (EPS) fell to $0.80 for the three months ended June 30, 2025, a decrease from $1.41 in the prior year.
• Operating income for the three months ended June 30, 2025, declined by 21.8% to $2,381 million, compared to $3,045 million in the prior year.
• The decline in net income and operating income was primarily due to $833 million in litigation charges and $41 million in losses related to Accountable Care assets during the quarter.
• For the six months ended June 30, 2025, total revenues increased by 7.7% to $193,503 million, while net income attributable to CVS Health decreased by 3.4% to $2,800 million.
• The Health Care Benefits segment's adjusted operating income increased by 39.4% for the three months and 97.7% for the six months, driven by favorable risk adjustment estimates and improved Government business performance.
• The Health Care Benefits segment recorded a $471 million premium deficiency reserve for its Group Medicare Advantage product line and a $448 million reserve for its individual exchange product line for the remainder of the 2025 coverage year.
• Medical membership in the Health Care Benefits segment decreased by 358,000 members compared to March 31, 2025, primarily due to declines in the individual exchange product line.
• The Health Services segment's adjusted operating income decreased by 17.8% for the three months and 3.1% for the six months, impacted by litigation charges and losses from Accountable Care assets.
• The Pharmacy & Consumer Wellness segment's adjusted operating income increased by 7.6% for the three months and 9.5% for the six months, driven by increased prescription and front store volume.
• Pharmacy same store sales increased by 18.1% for the three months, boosted by drug mix, including branded GLP-1 drugs, and a 6.4% increase in prescription volume.
• The company recorded a $542 million litigation charge related to the Omnicare long-term care business and a $291 million litigation charge related to PBM direct and indirect remuneration reporting practices.
• CVS Health substantially exited its ACO REACH program and divested its MSSP operations, incurring a pre-tax loss of $236 million from the MSSP divestiture.
• No share repurchases were made in the six months ended June 30, 2025, with $11.5 billion remaining under existing repurchase programs.
• The effective income tax rate increased to 38.5% for the three months ended June 30, 2025, primarily due to non-deductible litigation charges.

Sentiment

Score: 4

Explanation: The company experienced significant declines in net income and EPS due to substantial litigation charges and losses from divested businesses. While revenue growth was positive and some segments showed underlying strength, the large one-time costs and ongoing pressures from utilization and PBM pricing create a negative short-term outlook for profitability. The mixed debt rating outlook also adds to caution.

Positives

• Total revenues increased by 8.4% for the quarter and 7.7% for the six months, indicating strong top-line growth across operating segments.
• The Health Care Benefits segment showed significant improvement in adjusted operating income, increasing by 39.4% for the quarter and 97.7% for the six months, driven by favorable risk adjustment estimates and better Government business performance.
• Pharmacy & Consumer Wellness segment's adjusted operating income grew by 7.6% for the quarter and 9.5% for the six months, benefiting from increased prescription and front store volume.
• Pharmacy same store sales increased by a robust 18.1% for the quarter, driven by favorable drug mix, including GLP-1 drugs, and a 6.4% increase in prescription volume.
• The company finalized an enterprise-wide restructuring plan in Q3 2024, aiming for over $500 million in cost savings in 2025, which could improve future profitability.
• The 2026 Medicare Advantage payment rates are expected to increase by an average of 5.06% for the industry, which could benefit the Health Care Benefits segment.

Negatives

• Net income attributable to CVS Health plummeted by 42.3% for the three months ended June 30, 2025, and decreased by 3.4% for the six months, largely due to substantial litigation charges.
• Diluted EPS significantly declined to $0.80 for the quarter, down from $1.41 in the prior year, reflecting the impact of increased costs and litigation.
• Operating income decreased by 21.8% for the three months ended June 30, 2025, primarily due to $833 million in litigation charges and losses on Accountable Care assets.
• The Health Services segment's adjusted operating income decreased by 17.8% for the quarter and 3.1% for the six months, impacted by pharmacy client price improvements and a higher medical benefit ratio in its health care delivery business.
• The company recorded significant premium deficiency reserves totaling $902 million for the six months, indicating anticipated losses in individual exchange and Group Medicare Advantage product lines due to continued utilization pressure.
• Medical membership declined by 358,000 members compared to the previous quarter, primarily in the individual exchange product line.
• The Corporate/Other segment's adjusted operating loss increased by 17.3% for the quarter and 11.4% for the six months, driven by increased investments in colleagues and technology.
• The effective income tax rate rose significantly to 38.5% for the quarter due to the non-deductible nature of the litigation charges.

Risks

• Medical membership declines in Medicare and individual exchange products may lead to volatility in financial results.
• Elevated utilization levels are expected to continue pressuring the Health Care Benefits segment and health care delivery assets for the remainder of 2025, potentially leading to future goodwill impairment.
• Increases in utilization beyond current projections may necessitate additional premium deficiency reserves in the Health Care Benefits segment during 2025.
• The Medicaid business is experiencing medical cost pressures from higher acuity post-member redeterminations, with uncertainty regarding when state rate updates will fully offset these pressures.
• Continued sharing of rebates, fees, and discounts with pharmacy benefit management (PBM) clients, along with regulatory changes limiting retail network differential or spread, is expected to persist.
• Regulatory changes or shifts in consumer sentiment regarding immunizations could negatively impact national demand and financial results.
• Implementation of new tariffs or changes in tariffs could increase costs and disrupt supply chains, adversely impacting consumer demand or financial results.
• Consumer spend management and a shift to value, grocery, and digital retailers could lead to lower front store sales.
• Changes in U.S. and global capital markets could significantly affect interest rates and financing costs.
• Actions by ratings agencies, including debt rating changes, could impact future borrowing costs, access to capital markets, and new store operating lease costs.
• The company is exposed to changes in government policy, funding, and regulation of Medicare programs, including potential new reforms or surcharges and changes to risk adjustment mechanisms.
• Proposed or enacted legislation and regulations seeking to comprehensively regulate PBM activities could adversely affect the company's ability to conduct business on commercially reasonable terms and standardize PBM products.
• Ongoing legal proceedings, including class actions, government investigations, and litigation related to drug pricing, PBM practices, prescription processing, and controlled substances, pose significant financial and operational risks.
• CMS audits, particularly RADV audits, could result in material premium or fee refunds or adjustments, adversely affecting operating results, cash flows, and financial condition.

Future Outlook

The company anticipates continued pressure on its Health Care Benefits and health care delivery segments due to elevated utilization levels for the remainder of 2025. It expects to exit individual public health insurance exchanges by January 2026, which may cause membership volatility. The Medicaid business faces ongoing medical cost pressures, and PBM pricing dynamics are expected to continue limiting the company's ability to offer certain pricing structures. The company expects benefits from its enterprise-wide restructuring plan, aiming for over $500 million in cost savings in 2025.

Management Comments

• The company is creating new sources of value through its integrated model allowing it to expand into personalized, technology driven care delivery and health services, increasing access to quality care, delivering better health outcomes and lowering overall health care costs.
• The company plans to exit the states in which Aetna operates on the individual public health insurance exchanges effective January 2026.
• The company continues to share with clients a larger portion of rebates, fees and/or discounts received from pharmaceutical manufacturers.
• Marketplace dynamics and regulatory changes have limited the company's ability to offer plan sponsors pricing that includes retail network differential or spread, and these trends are expected to continue.
• The Pharmacy & Consumer Wellness segment is likely to benefit from incremental volume due to disruption across the retail pharmacy market, including the company's agreement to acquire the prescription files of certain Rite Aid pharmacies and acquire and operate certain Rite Aid stores.
• The company expects benefits from ongoing enterprise-wide cost savings initiatives and investments in efficiencies, which aim to reduce the company's operating cost structure in a way that improves the consumer experience and is sustainable.

Industry Context

The healthcare industry continues to face challenges from rising utilization rates, particularly in Medicare Advantage, and ongoing regulatory scrutiny of PBM practices. CVS Health's results reflect these broader trends, with increased healthcare costs and PBM pricing pressures impacting profitability. The company's strategic moves, such as divesting Accountable Care assets and exiting certain individual exchange markets, indicate a focus on optimizing its portfolio in response to market dynamics and regulatory changes. The acquisition of Rite Aid prescription files and stores positions the company to potentially gain market share amidst retail pharmacy disruption.

Corporate Governance

Legal Proceedings

• The company is named as a defendant in lawsuits alleging overcharging for prescription drugs by not submitting correct usual and customary prices, including a case asserting state false claims act claims by several state attorneys general.
• Multiple lawsuits and investigations are ongoing concerning the company's PBM practices, including allegations of anti-competitive and unfair practices that artificially increased insulin costs, with the FTC filing an administrative complaint.
• In United States ex rel. Behnke v. CVS Caremark Corporation, et al., a court ruled the company liable under the False Claims Act for certain claims, awarding damages and inviting briefing on trebling and penalties; the company recorded a litigation reserve and intends to appeal.
• The company is involved in ongoing opioid litigation, with a settlement resolving substantially all opioid claims by participating states and political subdivisions, but litigation is pending with non-participating entities and private parties.
• In December 2024, the DOJ intervened in a qui tam action, filing an amended complaint alleging violations of the federal Controlled Substances Act and False Claims Act related to opioid and other controlled substance prescriptions.
• In U.S. ex rel. Bassan et al. v. Omnicare, Inc. and CVS Health Corp., a jury found Omnicare and CVS Health Corporation liable for False Claims Act violations related to improper prescription filling, with Omnicare awarded approximately $136 million (tripled to $407 million) and penalties of $542 million, for which CVS Health Corporation is jointly and severally liable for $165 million; the company recorded litigation reserves and plans to appeal.
• In U.S. ex rel. Gill et al. v. CVS Health Corp. et al., the Delaware Attorney General's Office moved for partial intervention related to allegations under the Delaware false claims act concerning alleged overpayments.
• The company is a defendant in class actions and individual lawsuits regarding payment of claims for services rendered by in-network and out-of-network providers, alleging underpayment or failure to timely pay/administer claims.
• CMS regularly audits the company's performance for compliance with regulations and contracts, including risk adjustment data validation (RADV) audits, which could result in material premium refunds or adjustments.
• The company received Civil Investigative Demands (CIDs) from the DOJ concerning investigations of diagnosis codes related to risk adjustment payments under Medicare Parts C and D.
• In U.S. ex rel. Andrew Shea v. Aetna Life Insurance Company, et al., the U.S. Attorney's Office filed a complaint-in-intervention alleging the company paid kickbacks to insurance brokers to direct patients to Medicare Advantage plans and engaged in discriminatory conduct.
• Stockholder class action and derivative complaints allege omissions and misrepresentations related to the profitability of the Health Care Benefits segment, with motions to dismiss pending and derivative actions stayed.

Stakeholder Impact

• Shareholders: Significant decline in net income and EPS due to litigation charges may negatively impact shareholder value and sentiment. Ongoing share repurchase programs provide some support, but no repurchases were made in the current period.
• Customers/Members: Premium deficiency reserves and medical cost pressures could lead to higher premiums or reduced benefits in certain health plans. Exiting individual public health insurance exchanges will impact members in those states.
• Employees: The enterprise-wide restructuring plan aims to streamline the organization and improve efficiency, which may involve workforce adjustments. Increased investments in colleagues and technology are noted.
• Suppliers/Providers: PBM pricing pressures and ongoing litigation related to claims payments and provider networks could affect relationships and reimbursement terms with pharmaceutical manufacturers, wholesalers, and healthcare providers.
• Creditors: The company maintains compliance with debt covenants, but negative outlooks from Fitch and S&P on long-term debt could impact future borrowing costs and access to capital markets.

Next Steps

• The company plans to exit the states in which Aetna operates on the individual public health insurance exchanges effective January 2026.
• CMS plans to complete audits for Medicare Advantage payment years 2018 through 2024 by early 2026.
• The company intends to appeal the jury verdict and penalties in the Omnicare False Claims Act case.
• The company intends to appeal the court decision regarding PBM direct and indirect remuneration reporting practices.
• A trial in a case brought by a group of Florida hospitals related to opioid litigation is scheduled to begin in September 2025.
• The company will continue to defend contract awards it receives from government customers.
• The company expects benefits from its enterprise-wide restructuring plan, aiming to generate over $500 million in cost savings in 2025.

Key Dates

Recommendation

The filing presents a mixed financial picture. While CVS Health demonstrated strong revenue growth across its segments, particularly in Health Care Benefits and Pharmacy & Consumer Wellness, the significant decline in net income and diluted EPS due to substantial litigation charges is a major concern. The company is actively appealing these judgments, which introduces uncertainty regarding the final financial impact. Furthermore, ongoing industry challenges such as elevated healthcare utilization, Medicaid cost pressures, and PBM pricing dynamics persist. However, strategic initiatives like the enterprise-wide cost savings plan and the acquisition of Rite Aid assets offer potential for future operational improvements and market share gains. Given the substantial one-time impacts and the ongoing strategic adjustments, a 'hold' recommendation is appropriate, allowing investors to observe the outcomes of the appeals and the effectiveness of the cost-saving measures before making a more definitive investment decision.

Keywords

Healthcare, Pharmacy, PBM, Health Insurance, Medicare Advantage, Medicaid, Retail Pharmacy, SEC Filing, Earnings, Financial Results, Litigation, Risk Factors, Corporate Strategy, Acquisitions, Divestitures, Financial Reporting, CVS Health